Crispr technology may offer a new weapon against influenza. Researchers at the Peter Doherty Institute for Infection and Immunity in Melbourne are exploring Crispr's potential to treat both seasonal and pandemic flu strains. Virologist Wei Zhao presented the concept at the Pandemic Research Alliance Symposium in October. Crispr, known for gene editing in diseases like sickle cell, could be adapted to target the influenza virus's genetic code. This next-generation treatment aims to combat existing and emerging flu variants. The research focuses on using Crispr to cut strands of DNA. Scientists are now investigating the efficacy and safety of this novel approach. The development could revolutionize flu treatment strategies. Further research and clinical trials are planned to assess its real-world application.